189 related articles for article (PubMed ID: 26446946)
1. Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Meulendijks D; Lassen UN; Siu LL; Huitema AD; Karanikas V; Mau-Sorensen M; Jonker DJ; Hansen AR; Simcox ME; Schostack KJ; Bottino D; Zhong H; Roessler M; Vega-Harring SM; Jarutat T; Geho D; Wang K; DeMario M; Goss GD; Schellens JH
Clin Cancer Res; 2016 Feb; 22(4):858-67. PubMed ID: 26446946
[TBL] [Abstract][Full Text] [Related]
2. A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Lassen UN; Meulendijks D; Siu LL; Karanikas V; Mau-Sorensen M; Schellens JH; Jonker DJ; Hansen AR; Simcox ME; Schostack KJ; Bottino D; Zhong H; Roessler M; Vega-Harring SM; Jarutat T; Geho D; Wang K; DeMario M; Goss GD
Clin Cancer Res; 2015 Jan; 21(2):258-66. PubMed ID: 25388164
[TBL] [Abstract][Full Text] [Related]
3. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
Yin X; Luistro L; Zhong H; Smith M; Nevins T; Schostack K; Hilton H; Lin TA; Truitt T; Biondi D; Wang X; Packman K; Rosinski J; Berkofsky-Fessler W; Tang JP; Pant S; Geho D; Vega-Harring S; Demario M; Levitsky H; Simcox M
Clin Cancer Res; 2013 Oct; 19(20):5686-98. PubMed ID: 23974006
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
5. Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.
Gu L; Dai L; Cao C; Zhu J; Ding C; Xu HB; Qiu L; Di W
PLoS One; 2013; 8(3):e57436. PubMed ID: 23469193
[TBL] [Abstract][Full Text] [Related]
6. TWEAK/Fn14 signaling in tumors.
Hu G; Zeng W; Xia Y
Tumour Biol; 2017 Jun; 39(6):1010428317714624. PubMed ID: 28639899
[TBL] [Abstract][Full Text] [Related]
7. Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis.
Pettersen I; Baryawno N; Abel F; Bakkelund WH; Zykova SN; Winberg JO; Moens U; Rasmuson A; Kogner P; Johnsen JI; Sveinbjörnsson B
Int J Oncol; 2013 Apr; 42(4):1239-48. PubMed ID: 23443741
[TBL] [Abstract][Full Text] [Related]
8. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke.
Inta I; Frauenknecht K; Dörr H; Kohlhof P; Rabsilber T; Auffarth GU; Burkly L; Mittelbronn M; Hahm K; Sommer C; Schwaninger M
J Neurol Sci; 2008 Dec; 275(1-2):117-20. PubMed ID: 18793781
[TBL] [Abstract][Full Text] [Related]
9. Expression of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor, fibroblast growth factor-inducible 14 protein (Fn14), in healthy tissues and in tissues affected by periodontitis.
Kataria NG; Bartold PM; Dharmapatni AA; Atkins GJ; Holding CA; Haynes DR
J Periodontal Res; 2010 Aug; 45(4):564-73. PubMed ID: 20546112
[TBL] [Abstract][Full Text] [Related]
10. TWEAK signals through JAK-STAT to induce tumor cell apoptosis.
Chapman MS; Wu L; Amatucci A; Ho SN; Michaelson JS
Cytokine; 2013 Jan; 61(1):210-7. PubMed ID: 23107828
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis.
Xia Y; Campbell SR; Broder A; Herlitz L; Abadi M; Wu P; Michaelson JS; Burkly LC; Putterman C
Clin Immunol; 2012 Nov; 145(2):108-21. PubMed ID: 22982296
[TBL] [Abstract][Full Text] [Related]
12. Development of an Fn14 agonistic antibody as an anti-tumor agent.
Michaelson JS; Amatucci A; Kelly R; Su L; Garber E; Day ES; Berquist L; Cho S; Li Y; Parr M; Wille L; Schneider P; Wortham K; Burkly LC; Hsu YM; Joseph IB
MAbs; 2011; 3(4):362-75. PubMed ID: 21697654
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis-like weak inducer of apoptosis as a proinflammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by inflammation but not hypoxia.
Vendrell J; Maymó-Masip E; Tinahones F; García-España A; Megia A; Caubet E; García-Fuentes E; Chacón MR
J Clin Endocrinol Metab; 2010 Jun; 95(6):2983-92. PubMed ID: 20382683
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats.
Mustonen E; Säkkinen H; Tokola H; Isopoussu E; Aro J; Leskinen H; Ruskoaho H; Rysä J
Acta Physiol (Oxf); 2010 May; 199(1):11-22. PubMed ID: 20082609
[TBL] [Abstract][Full Text] [Related]
15. HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes.
Moreno JA; Sastre C; Madrigal-Matute J; Muñoz-García B; Ortega L; Burkly LC; Egido J; Martín-Ventura JL; Blanco-Colio LM
Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):612-20. PubMed ID: 23288170
[TBL] [Abstract][Full Text] [Related]
16. The tumor necrosis factor superfamily members TWEAK, TNFSF15 and fibroblast growth factor-inducible protein 14 are upregulated in proliferative diabetic retinopathy.
Abu El-Asrar AM; De Hertogh G; Nawaz MI; Siddiquei MM; Van den Eynde K; Mohammad G; Opdenakker G; Geboes K
Ophthalmic Res; 2015; 53(3):122-30. PubMed ID: 25676319
[TBL] [Abstract][Full Text] [Related]
17. TWEAK-Fn14 pathway activation after exercise in human skeletal muscle: insights from two exercise modes and a time course investigation.
Raue U; Jemiolo B; Yang Y; Trappe S
J Appl Physiol (1985); 2015 Mar; 118(5):569-78. PubMed ID: 25539934
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis.
Kawashima R; Kawamura YI; Oshio T; Son A; Yamazaki M; Hagiwara T; Okada T; Inagaki-Ohara K; Wu P; Szak S; Kawamura YJ; Konishi F; Miyake O; Yano H; Saito Y; Burkly LC; Dohi T
Gastroenterology; 2011 Dec; 141(6):2119-2129.e8. PubMed ID: 21893119
[TBL] [Abstract][Full Text] [Related]
19. ALKBH3 contributes to survival and angiogenesis of human urothelial carcinoma cells through NADPH oxidase and tweak/Fn14/VEGF signals.
Shimada K; Fujii T; Tsujikawa K; Anai S; Fujimoto K; Konishi N
Clin Cancer Res; 2012 Oct; 18(19):5247-55. PubMed ID: 22850567
[TBL] [Abstract][Full Text] [Related]
20. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis.
Dohi T; Borodovsky A; Wu P; Shearstone JR; Kawashima R; Runkel L; Rajman L; Dong X; Scott ML; Michaelson JS; Jakubowski A; Burkly LC
Gastroenterology; 2009 Mar; 136(3):912-23. PubMed ID: 19109961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
